title: Clinical correlation between brain natriutetic peptide and anthracyclin-induced cardiac toxicity.
abstract: OBJECTIVE
  Anthracycline can effectively treat hematologic malignancies, but has significant risk of cardiotoxicity. We measured the clinical correlation between brain natriuretic peptide (BNP) and anthracycline-induced cardiotoxicity.
  
  
  METHODS
  Between March 2005 and March 2007, 86 patients with acute leukemia, malignant lymphoma, or multiple myeloma receiving systemic chemotherapy with anthracycline were enrolled in the Department of Hemato-oncology, Kosin University Gospel Hospital. We investigated the relationship between BNP level and cardiotoxicity through echocardiography, electrocardiography, BNP levels, and symptoms of heart failure at each chemotherapy cycle.
  
  
  RESULTS
  Of the 86 participants (mean age, 48.5 years; range 20 approximately 65 years), cardiotoxicity developed in 21 patients (24.4%), with 2 patients showing arrhythmia only, 17 patients with transient aspects of heart failure, and 2 patients with chronic heart failure. Cardiotoxicity related to serum BNP level, age, cumulative dose of anthracycline, accompanying chronic disease, and elevated level of troponin-I. Heart failure was more common if BNP levels reached 100 pg/ml at least once.
  
  
  CONCLUSIONS
  The clinical correlation between BNP and cardiotoxicity was significant in patients with systemic anthracycline chemotherapy. A prospective clinical trial will be needed to identify the causal relationship between serum BNP level and cardiotoxicity.
authors.affiliation: Department of Internal Medicine, Kosin University Gospel Hospital, Busan, Korea.
authors.forename: Ho Sup
authors.initials: HS
authors.lastname: Lee
authors.forename: Chang Bae
authors.initials: CB
authors.lastname: Son
authors.forename: Seong Hoon
authors.initials: SH
authors.lastname: Shin
authors.forename: Yang Soo
authors.initials: YS
authors.lastname: Kim
references.citation: Am J Med. 1978 Nov;65(5):823-32
references.pmid: 707541
references.citation: Oncology. 1996 Nov-Dec;53(6):461-70
references.pmid: 8960141
references.citation: Eur J Haematol. 1999 Feb;62(2):135-41
references.pmid: 10052718
references.citation: J Clin Oncol. 2005 Nov 1;23(31):7820-6
references.pmid: 16258084
references.citation: J Clin Oncol. 2004 Aug 1;22(15):3070-9
references.pmid: 15284257
references.citation: Ann Intern Med. 1979 Nov;91(5):710-7
references.pmid: 496103
references.citation: J Clin Oncol. 2003 Jun 15;21(12):2349-56
references.pmid: 12805337
references.citation: N Engl J Med. 1988 Sep 22;319(12):745-52
references.pmid: 3137469
references.citation: J Clin Oncol. 2004 Mar 1;22(5):769-73
references.pmid: 14990630
references.citation: J Clin Oncol. 1997 Apr;15(4):1333-40
references.pmid: 9193324
references.citation: Clin Sci (Lond). 2001 Dec;101(6):601-7
references.pmid: 11724646
references.citation: J Clin Oncol. 2001 Mar 1;19(5):1444-54
references.pmid: 11230490
references.citation: J Clin Oncol. 2005 Oct 20;23(30):7685-96
references.pmid: 16234530
references.citation: J Clin Oncol. 1998 Feb;16(2):545-50
references.pmid: 9469339
references.citation: Semin Oncol. 2003 Dec;30(6):730-9
references.pmid: 14663774
references.citation: Med Pediatr Oncol. 2001 Jul;37(1):4-9
references.pmid: 11466716
references.citation: Cancer Res. 1998 Jan 15;58(2):195-7
references.pmid: 9443390
references.citation: Am Heart J. 2001 Mar;141(3):367-74
references.pmid: 11231433
references.citation: N Engl J Med. 1995 Jun 29;332(26):1738-43
references.pmid: 7760889
references.citation: J Am Coll Cardiol. 2000 Aug;36(2):517-22
references.pmid: 10933366
references.citation: J Clin Oncol. 2004 May 15;22(10):1864-71
references.pmid: 15143078
references.citation: N Engl J Med. 1971 Dec 23;285(26):1441-6
references.pmid: 5122894